Aging and CLL amplify fatigue, anemia, and infection risks, impacting physical activity and recovery. Tailored strategies, such as anti-inflammatory diets and strength training, can enhance resilience ...

Pirtobrutinib significantly improved progression-free survival in untreated CLL/SLL patients compared to standard chemoimmunotherapy in the BRUIN CLL-313 trial. Early trends suggest potential overall ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, ...